I predict BMY already offer the bid, but LP is waiting the topline result to bargin the price. At 2017, there was a rumor that Roche passed their board to acquire nwbo. May be LP have rejected it and wait topline result at 2018
Merck can afford 15-22B easily to acquire nwbo, just want their competitor BMY can't to flight with them. The facts show that Dcvax suitable for different kinds of cancer.
Just BMY, Merch and Roche must has interest to acquire nwbo.
Market Data 
Markets 
AI
